Health company Quanterix Corporation (NASDAQ:QTRX) reported on Monday the receipt of the U.S. Food and Drug Administration's Breakthrough Device designation for Simoa phospho-Tau 181 blood test in the diagnostic aid and evaluation of Alzheimer's Disease (AD).
The company revealed the Simoa pTau-181 (pTau-181) test is a semiquantitative immunoassay intended for the measurement of pTau-181 concentration in human serum and plasma using its HD-X immunoassay system.
Under the US FDA's breakthrough device designation, the proposed indication include the use of the test results in adult patients aged 50 years and over as well as use the patient's AD cognitive impairment and other causes of cognitive decline in the diagnostic evaluation of AD.
In addition, the test results will be interpreted in conjunction with other diagnostic tools to establish a final clinical diagnosis. The FDA's breakthrough device designation is designed to enable accelerated development, assessment and review processes, with the intention to provide patients with more timely access to breakthrough technologies or devices, concluded the company.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia